
[Dipivefrin Hydrochloride](#)

Type of Posting: Notice of Intent to Revise

Posting Date: 30– April –2020

Targeted Official Date: 01–Dec–2021, *USP–NF* 2021 Issue 3

Expert Committee: Chemical Medicines Monographs 3

In accordance with section 7.04 (c) of the 2015–2020 Rules and Procedures of the Council of Experts, this is to provide notice that the Chemical Medicines Monographs 3 Expert Committee intends to omit the Dipivefrin Hydrochloride monograph.

USP may propose to omit a monograph from the USP–NF if the article is no longer marketed in the United States and where the monograph is not necessary to serve a public health need. Based on evaluation of the monograph, the USP Chemical Medicines Monographs 3 Expert Committee has determined that the Dipivefrin Hydrochloride monograph should be proposed for omission in the *Pharmacopeial Forum* (PF).

USP Dipivefrin Hydrochloride RS, associated with this monograph, is currently unavailable. USP does not intend to develop a replacement lot for USP Dipivefrin Hydrochloride RS in anticipation of the omission of this monograph.

It is anticipated that the proposed revision will be published in *PF* 46(5) [Sep.-Oct. 2020].

Should you have any questions, please contact Morgan Puderbaugh, Senior Scientific Liaison (301–816–8373 or mxp@usp.org).